Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 16 for Myelodysplastic syndromes

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Study to Evaluate APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study to Evaluate Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/ Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

    Rochester, MN

  4. Evaluating SNS-301 in High Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

    Rochester, MN

  5. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

    Jacksonville, FL, Rochester, MN

  7. A Study to Determine the Recommended Dose of CYAD-02 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients

    Jacksonville, FL

  8. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Rochester, MN

  10. A Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk Myelodysplastic Syndromes (MDS)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer